With a market capitalization (market cap) of $4.2B — a measure of how much the company is worth — AbCellera Biologics Inc. ranks #1,500 among the 2,510 companies tracked, and 178th in Healthcare as of October 3, 2026. Shares trade at $13.74, down 1.22% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $4.2B | +305.05% | $13.74 |
| 2025 | Dec 31, 2025 | $1.04B | +18.83% | $3.42 |
| 2024 | Dec 31, 2024 | $872.24M | -47.50% | $2.93 |
| 2023 | Dec 29, 2023 | $1.66B | -42.74% | $5.71 |
| 2022 |
Ranking figure $4.2B as of October 3, 2026.
AbCellera Biologics Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $13.74 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $4.2B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 298,707,082 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, AbCellera Biologics Inc. (ABCL) is worth $4.2B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, AbCellera Biologics Inc.’s book equity is about $966.9M. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $4.2B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
AbCellera Biologics Inc. ranks #1,500 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #178 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| Dec 30, 2022 |
| $2.9B |
| -28.53% |
| $10.13 |
| 2021 | Dec 31, 2021 | $4.06B | — | $14.30 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #1497 | Par Pacific Holdings, Inc. PARR | $4.21B | -2.56% |
| #1498 | Brookfield Renewable Corporation BEPC | $4.21B | +0.11% |
| #1499 | MakeMyTrip Limited MMYT | $4.2B | -6.55% |
| #1501 | The Brink's Company BCO | $4.19B | +1.83% |
| #1502 | Centerra Gold Inc. CGAU | $4.19B | -0.51% |
| #1503 | The GEO Group, Inc. GEO | $4.19B | +1.85% |
AbCellera Biologics Inc.’s ranking market cap of $4.2B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 298,707,082. The historical market-cap series last observed $4.2B on October 2, 2026.
Over the past year, AbCellera Biologics Inc.’s market cap is up 135.04%, using historical market-cap records rather than today’s share count applied to past prices.
AbCellera Biologics Inc. (ABCL) shares trade at $13.74, down 1.22% on the day, as of October 3, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.